JP2013521233A - Ａβを標的とする免疫療法のＰＥＴモニタリング - Google Patents

Ａβを標的とする免疫療法のＰＥＴモニタリング Download PDF

Info

Publication number
JP2013521233A
JP2013521233A JP2012555201A JP2012555201A JP2013521233A JP 2013521233 A JP2013521233 A JP 2013521233A JP 2012555201 A JP2012555201 A JP 2012555201A JP 2012555201 A JP2012555201 A JP 2012555201A JP 2013521233 A JP2013521233 A JP 2013521233A
Authority
JP
Japan
Prior art keywords
group
pet
patient
brain
amyloid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012555201A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013521233A5 (https=
Inventor
ロナルド ブラック，
マイケル グランドマン，
Original Assignee
ヤンセン アルツハイマー イミュノセラピー
ワイス・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン アルツハイマー イミュノセラピー, ワイス・エルエルシー filed Critical ヤンセン アルツハイマー イミュノセラピー
Publication of JP2013521233A publication Critical patent/JP2013521233A/ja
Publication of JP2013521233A5 publication Critical patent/JP2013521233A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0429—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K51/0431—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012555201A 2010-02-25 2011-02-25 Ａβを標的とする免疫療法のＰＥＴモニタリング Pending JP2013521233A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30825310P 2010-02-25 2010-02-25
US61/308,253 2010-02-25
PCT/US2011/026365 WO2011106732A1 (en) 2010-02-25 2011-02-25 Pet monitoring of ab-directed immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016093421A Division JP2016185964A (ja) 2010-02-25 2016-05-06 Ａβを標的とする免疫療法のＰＥＴモニタリング

Publications (2)

Publication Number Publication Date
JP2013521233A true JP2013521233A (ja) 2013-06-10
JP2013521233A5 JP2013521233A5 (https=) 2014-09-25

Family

ID=44507245

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012555201A Pending JP2013521233A (ja) 2010-02-25 2011-02-25 Ａβを標的とする免疫療法のＰＥＴモニタリング
JP2016093421A Pending JP2016185964A (ja) 2010-02-25 2016-05-06 Ａβを標的とする免疫療法のＰＥＴモニタリング

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016093421A Pending JP2016185964A (ja) 2010-02-25 2016-05-06 Ａβを標的とする免疫療法のＰＥＴモニタリング

Country Status (4)

Country Link
US (1) US20130084245A1 (https=)
EP (1) EP2538982A4 (https=)
JP (2) JP2013521233A (https=)
WO (1) WO2011106732A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021515005A (ja) * 2018-03-01 2021-06-17 トライジェミナ， インコーポレイテッド 標識オキシトシンならびに製造および使用の方法
JP2021535378A (ja) * 2018-08-21 2021-12-16 コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. アミロイドスクリーニング方法及び装置
JP2023506450A (ja) * 2019-12-11 2023-02-16 アンベテックス ピーティーワイ エルティーディー 拡張機能障害の防止及び治療のためのアミロイドベータ抗体又はワクチンを含む療法組成物

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
SI2579042T1 (sl) 2011-10-04 2014-09-30 Affiris Ag Postopek za detektiranje Ass-specifičnih protiteles v biološkem vzorcu
JP6100792B2 (ja) 2011-11-16 2017-03-22 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 灰白質における脳アミロイドを算出及び表示する方法
RU2014153675A (ru) * 2012-07-03 2016-08-27 Янссен Альцгеймер Иммунотерапи Антитела к с-концевым и центральным эпитопам а-бета
CN106831799B (zh) * 2016-12-20 2018-12-21 四川大学 羟基苯乙烯吡啶曼尼希碱类化合物、其制备方法和用途
KR102031652B1 (ko) * 2018-01-19 2019-10-14 서울대학교산학협력단 전이체 단백질 과발현 관련 질환의 양성자방출단층촬영 방사성추적자, 형광영상 진단 및 광역학 치료를 위한 전이체 단백질 표적 리간드 및 이의 제조방법
MX2021000778A (es) * 2018-07-24 2021-03-31 Eisai R&D Man Co Ltd Metodos de tratamiento y prevencion de la enfermedad de alzheimer.

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050214222A1 (en) * 2004-02-13 2005-09-29 Mckinnon Stuart J In vivo imaging of amyloid plaques in glaucoma using intravenous injectable dyes
JP2008505115A (ja) * 2004-07-02 2008-02-21 ユニバーシティー オブ ピッツバーグ 抗アミロイド治療の有効性に対する代用マーカーとしてのアミロイドイメージング
WO2008114801A1 (en) * 2007-03-12 2008-09-25 National Institute Of Radiological Sciences Pet visualization of amyloid-associated neuroinflammation in the brain
WO2008131298A2 (en) * 2007-04-18 2008-10-30 Elan Pharma International Limited Prevention and treatment of cerebral amyloid angiopathy
WO2009017467A1 (en) * 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
WO2009052439A2 (en) * 2007-10-17 2009-04-23 Elan Pharma International Limited Immunotherapy regimes dependent on apoe status

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2275570T3 (es) 1999-12-08 2007-06-16 Intellect Neurosciences, Inc. Peptidos amiloides beta quimericos.
ES2389811T3 (es) 2000-06-28 2012-10-31 Prana Biotechnology Limited Oligómeros de amiloide beta para uso en el tratamiento, el alivio o la prevención de la enfermedad de Alzheimer
EP1309341A2 (en) 2000-07-07 2003-05-14 Lars Lannfelt Prevention and treatment of alzheimer's disease
US6395837B1 (en) 2000-08-03 2002-05-28 King Industries, Inc. Alkylated aryl disulfonic acid catalysts for crosslinking polyethylene
SI1524994T1 (sl) 2002-07-19 2011-08-31 Cytos Biotechnology Ag Sestavki cepiv, ki vsebujejo amiloidne beta 1-6 antigenske mreĹľe
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US20040242845A1 (en) 2003-02-21 2004-12-02 Nicolau Yves Claude Methods and compositions comprising supramolecular antigenic constructs and antibodies elicited against them
US20050123553A1 (en) 2003-07-30 2005-06-09 Alon Monsonego Amyloid beta-peptide and methods of use
AT413946B (de) 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
NZ562434A (en) 2005-05-05 2010-04-30 Merck & Co Inc Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050214222A1 (en) * 2004-02-13 2005-09-29 Mckinnon Stuart J In vivo imaging of amyloid plaques in glaucoma using intravenous injectable dyes
JP2008505115A (ja) * 2004-07-02 2008-02-21 ユニバーシティー オブ ピッツバーグ 抗アミロイド治療の有効性に対する代用マーカーとしてのアミロイドイメージング
WO2008114801A1 (en) * 2007-03-12 2008-09-25 National Institute Of Radiological Sciences Pet visualization of amyloid-associated neuroinflammation in the brain
WO2008131298A2 (en) * 2007-04-18 2008-10-30 Elan Pharma International Limited Prevention and treatment of cerebral amyloid angiopathy
WO2009017467A1 (en) * 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
WO2009052439A2 (en) * 2007-10-17 2009-04-23 Elan Pharma International Limited Immunotherapy regimes dependent on apoe status

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021515005A (ja) * 2018-03-01 2021-06-17 トライジェミナ， インコーポレイテッド 標識オキシトシンならびに製造および使用の方法
JP2021535378A (ja) * 2018-08-21 2021-12-16 コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. アミロイドスクリーニング方法及び装置
JP7442505B2 (ja) 2018-08-21 2024-03-04 コーニンクレッカ フィリップス エヌ ヴェ アミロイドスクリーニング方法及び装置
JP2023506450A (ja) * 2019-12-11 2023-02-16 アンベテックス ピーティーワイ エルティーディー 拡張機能障害の防止及び治療のためのアミロイドベータ抗体又はワクチンを含む療法組成物

Also Published As

Publication number Publication date
EP2538982A1 (en) 2013-01-02
WO2011106732A1 (en) 2011-09-01
JP2016185964A (ja) 2016-10-27
EP2538982A4 (en) 2016-02-17
US20130084245A1 (en) 2013-04-04

Similar Documents

Publication Publication Date Title
JP2016185964A (ja) Ａβを標的とする免疫療法のＰＥＴモニタリング
JP5745853B2 (ja) ＡｐｏＥ状態に依存する免疫療法レジメ
US9272030B2 (en) Use of tau to monitor immunotherapy
JP5889529B2 (ja) アミロイド原性疾患の処置
US20150353631A1 (en) C-terminal and central epitope a-beta antibodies
JP2011510913A (ja) アミロイドーシスの処置および予防
US20250243269A1 (en) Anti-fsh antibodies for neurodegenerative diseases
JP2014001232A (ja) アミロイド原性疾患の処置
TW202530252A (zh) 降低抗體免疫原性及改良抗體穩定性之組成物及方法
AU2016208353A1 (en) Immunotherapy regimes dependent on ApoE status
AU2013209361A1 (en) Immunotherapy regimes dependent on ApoE status
JP2016047839A (ja) アミロイド原性疾患の処置
BRPI0823507A2 (pt) Usos de um anticorpo que se liga especificamente a um epítopo de terminal n de abeta e de uma medição de número de cópia de apoe4

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140224

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150730

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160506

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160928

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20161006

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20161118